Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 5, Mai 2014
Page(s) 551 - 557
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143005019
Publié en ligne 13 juin 2014
  1. Oleske J, Minnefor A, Cooper R, Jr, et al. Immune deficiency syndrome in children. JAMA 1983 ; 249 : 2345–2349. [CrossRef] [PubMed] [Google Scholar]
  2. Rubinstein A, Sicklick M, Gupta A, et al. Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA 1983 ; 249 : 2350–2356. [CrossRef] [PubMed] [Google Scholar]
  3. Rapport 2013 sur la prise en charge médicale des personnes vivant avec le VIH. Disponible à : http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf [Google Scholar]
  4. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS french perinatal cohort. AIDS 2008 ; 22 : 289–299. [CrossRef] [PubMed] [Google Scholar]
  5. Frange P, Chaix ML, Veber F, Blanche S. Missed opportunities for HIV testing in pregnant women and children living in France. Pediatr Infect Dis J 2014 ; 33 : e60–e62. [CrossRef] [PubMed] [Google Scholar]
  6. Mayaux MJ, Burgard M, Teglas JP, et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The french pediatric HIV infection study group. JAMA 1996 ; 275 : 606–610. [CrossRef] [PubMed] [Google Scholar]
  7. Blanche S, Dollfus C, Faye A, et al. Pediatric aids, 30 years later. Arch Pediatr 2013 ; 20 : 890–896. [CrossRef] [PubMed] [Google Scholar]
  8. Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART area. J Acquir Immune Defic Syndr 2010 ; 53 : 86–94. [CrossRef] [PubMed] [Google Scholar]
  9. Dollfus C, Le Chenadec J, Faye A, et al. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the french perinatal cohort (EPF/ANRS CO10). Clin Infect Dis 2010 ; 51 : 214–224. [CrossRef] [PubMed] [Google Scholar]
  10. Héraud-Bousquet V, Lot F, Esvan M, et al. A three-source capture-recapture estimate of the number of new HIV diagnoses in children in France from 2003-2006 with multiple imputation of a variable of heterogeneous catchability. BMC Infect Dis 2012 ; 12 : 251. [CrossRef] [PubMed] [Google Scholar]
  11. Pursuing later treatment options II (PLATO II) project team for the collaboration of observational HIV epidemiological research Europe (COHERE), Castro H, Judd A, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011 ; 377 : 1580–1587 [CrossRef] [PubMed] [Google Scholar]
  12. Sigaloff KC, Calis JC, Geelen SP, et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 2011 ; 11 : 769–779. [CrossRef] [PubMed] [Google Scholar]
  13. Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. J Pediatr Endocrinol Metab 2013 ; 21 : 1–10. [Google Scholar]
  14. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr 2012 ; 60 : 369–376. [CrossRef] [PubMed] [Google Scholar]
  15. Morén C, Noguera-Julian A, Garrabou G, et al. Mitochondrial evolution in HIV-infected children receiving first- or second-generation nucleoside analogues. J Acquir Immune Defic Syndr 2012 ; 60 : 111–116. [CrossRef] [PubMed] [Google Scholar]
  16. Saitoh A, Fenton T, Alvero C, et al. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007 ; 5 : 4236–4242. [CrossRef] [Google Scholar]
  17. Payne BAI, Wilson IJ, Hateley CA, et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011 ; 43 : 806–810. [CrossRef] [PubMed] [Google Scholar]
  18. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008 ; 152 : 582–584. [CrossRef] [PubMed] [Google Scholar]
  19. Lambotte O. Les patients HIV controllers. Med Sci (Paris) 2012 ; 28 : 172–178. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  20. Warszawski J, Lechenadec J, Faye A, et al. Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French pediatric cohort. Clin Infect Dis 2007 ; 45 : 785–794. [CrossRef] [PubMed] [Google Scholar]
  21. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013 ; 9 : e1003211. [CrossRef] [PubMed] [Google Scholar]
  22. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013 ; 208 : 1202–1211. [CrossRef] [PubMed] [Google Scholar]
  23. Hocqueloux L, Avettand-Fènoël V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013 ; 68 : 1169–1178. [CrossRef] [PubMed] [Google Scholar]
  24. Persaud D, Palumbo PE, Ziemniak C, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012 ; 26 : 1483–1490. [CrossRef] [PubMed] [Google Scholar]
  25. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013 ; 369 : 1828–1835. [CrossRef] [PubMed] [Google Scholar]
  26. Kent SJ, Reece JC, Petravic J, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis 2013 ; 13 : 614–621. [CrossRef] [PubMed] [Google Scholar]
  27. Patel K, Van Dyke RB, Mittleman MA, et al. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. AIDS 2012 ; 26 : 2027–2037. [CrossRef] [PubMed] [Google Scholar]
  28. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J 2013 ; 32 : 495–500. [CrossRef] [PubMed] [Google Scholar]
  29. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Safety and efficacy of etravirine in HIV-1 infected, treatment-experienced children and adolescents (6 to < 18 years): week 24 primary analysis of the phase II PIANO study [abstract TULBPE027], 6th IAS Conference on HIV pathogenesis, treatment and prevention, Rome, 2011 ; pp. 17–20. [Google Scholar]
  30. Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 2014 ; 58 : 413–422. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.